Business Context and Reporting Period
This Form 8-K filing by Galectin Therapeutics Inc. (Nevada) was submitted on June 15, 2018, reporting events occurring on June 14, 2018. The filing addresses Item 5.02 regarding the departure of directors or certain officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes.
Material Changes
- Executive Departure: Peter Traber, MD, resigned as President and Chief Executive Officer.
- Effective Date: Although originally scheduled for July 6, 2018, the resignation was accelerated to become effective on June 14, 2018.
- Succession: Harold H. Shlevin, Ph.D., was appointed to replace Dr. Traber in the roles of President and CEO.
- Transition Period: Dr. Traber remains an employee of the Company through July 6, 2018.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Confirm the official appointment date and background of the new CEO, Harold H. Shlevin, Ph.D.
- Review any subsequent filings for details on the separation agreement or compensation arrangements for the departing CEO.
- Verify the Company's current cash position and runway, as this filing does not disclose financial status.